Japan's Otsuka to buy Avanir for $3.5 billion ahead of patent cliff

The deal, Otsuka's biggest according to Thomson Reuters data, comes as the company aims to beef up its product pipeline ahead of a so-called "patent cliff" after April 2015, when its U.S. patent for schizophrenia drug Abilify expires and opens the way to generic competition.